ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...4647484950515253545556...129130»
  • ||||||||||  ivermectin oral / Generic mfg.
    REPURPOSED APPROVED THERAPIES FOR OUTPATIENT TREATMENT OF PATIENTS WITH COVID-19 ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_1094;    
    We assessed the efficacy of multiple interventions, including fluvoxamine, metformin and ivermectin, with others still ongoing, in preventing hospitalizations defined as either retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19...The trial continues to recruit and randomize patients to placebo, Peginterferon Lambda and doxazosin for continued evaluation...Other interventions will continue to be evaluated in this platform trial. These findings can inform clinical treatment guidelines for the outpatient management of patients with early-onset COVID-19.
  • ||||||||||  ivermectin oral / Generic mfg.
    Strongyloides stercoralis hyperinfection syndrom mimicking severe acute colitis (PAVILLON 1; ROOM: ANTWERP [VIRTUAL]) -  Feb 7, 2022 - Abstract #BWG2022BWG_232;    
    He has a significant past medical history of Ulcerative Colitis (UC) diagnosed in 2012 and currently treated with tofacitinib 10 mg twice daily...Flare of inflammatory bowel disease is usually treated with corticosteroids which has been proven to be the leading risk factor for the most severe forms of strongyloidiasis. Although it is a rare entity in our country, the correct diagnosis and treatment of Strongyloides hyperinfection syndrom is of critical importance to avoid UC treatment escalation (including colectomy) as it is a life-threatening disease.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection. (Pubmed Central) -  Feb 4, 2022   
    Although the clinical use of ionophores such as Amphotericin B, Bedaquiline and Ivermectin highlight the utility of ionophores in modern medicine, for many other ionophore compounds issues surrounding toxicity, bioavailability or lack of in vivo efficacy studies have hindered clinical development...As such, ionophores remain a latent therapeutic avenue to address both the global burden of antimicrobial resistance, and the unmet clinical need for new antimicrobial therapies. This review will provide an overview of the broad-spectrum antimicrobial and immunomodulatory properties of ionophores, and their potential uses in clinical medicine for combatting infection.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Review, Journal:  An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. (Pubmed Central) -  Feb 3, 2022   
    Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved...We focus on currently recommended therapeutic agents, including steroids, various monoclonal antibodies, remdesivir, baricitinib, anticoagulants and PAXLOVID™ summarizing the latest original studies and meta-analyses...The results of recent studies report that hydroxychloroquine and convalescent plasma demonstrate no efficacy against SARS-CoV-2 infection. Lastly, we summarize the studies on various drugs with incoherent or insufficient data concerning their effectiveness, such as amantadine, ivermectin, or niclosamide.
  • ||||||||||  ivermectin oral / Generic mfg.
    New P3 trial:  Ivermectin to prevent Coronavirus (EUDRACT) -  Feb 3, 2022   
    P3,  N=1000, Not yet recruiting, 
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial completion date, Trial primary completion date:  ISSC: Ivermectin Safety in Small Children (clinicaltrials.gov) -  Feb 3, 2022   
    P2,  N=398, Not yet recruiting, 
    Lastly, we summarize the studies on various drugs with incoherent or insufficient data concerning their effectiveness, such as amantadine, ivermectin, or niclosamide. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Mar 2023
  • ||||||||||  ivermectin oral / Generic mfg.
    Enrollment change, Trial withdrawal:  ZIT: The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19 (clinicaltrials.gov) -  Feb 3, 2022   
    P4,  N=0, Withdrawn, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Mar 2023 N=800 --> 0 | Not yet recruiting --> Withdrawn